Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience reports promising interim results from their diabetes animal study, showcasing that their DehydraTECH-liraglutide and certain DehydraTECH-CBD formulations reduced blood sugar levels, outperforming other tested groups. These findings suggest potential for DehydraTECH-CBD in diabetes control, particularly when used with GLP-1 drugs.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.